The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease

Mohamed I. Elsaid, Vinod K. Rustgi, Nicole Loo, Kavita Aggarwal, Josephine Li-McLeod, Xiaoli Niu, Fred Poordad

Resultado de la investigación: Articlerevisión exhaustiva

6 Citas (Scopus)


Background: Thrombocytopenia (TCP), a common complication of chronic liver disease (CLD), can cause uncontrolled bleeding during procedures. As such, CLD patients with TCP and platelet counts <50,000/μL often receive prophylactic platelet transfusions before invasive procedures. However, platelet transfusions are associated with clinical complications, which may result in increased healthcare utilization and costs. Objective: This retrospective database analysis describes the clinical and economic burden in CLD patients with TCP, CLD patients without TCP, and CLD patients with TCP who receive platelet transfusions. Methods: Adult CLD patients with or without TCP were identified in the IBM MarketScan Commercial Claims and Medicare Supplemental data from 1 January 2012 to 31 December 2015. CLD patients with or without TCP were propensity-score matched (1:1) for the analysis of annual healthcare utilization and costs. Platelet transfusions among CLD patients with TCP were identified using procedure codes. Results: Of the 601,626 patients with CLD, 8,292 (1.4%) patients with TCP were matched to patients without TCP. Among CLD patients with TCP, 981 (11.8%) patients received ≥1 platelet transfusions and met inclusion/exclusion criteria. Compared to patients without TCP, CLD patients with TCP had more complications, including higher prevalence of neutropenia (11.4% vs 2.9%) and bleeding events (21.4% vs 10.9%), greater resource utilization including greater average hospital admissions (1.2 vs 0.7, p <.01), greater average ER visits (2.1 vs 1.3, p <.01), higher average outpatient office visits (20.1 vs 18.4, p <.01), and higher average healthcare costs including total costs (p <.01), inpatient costs (p <.01), ER visit costs (p <.01), and outpatient office visit costs (p <.01). The mean annual total costs in CLD and TCP patients with platelet transfusions were $206,396. Conclusions: CLD patients with TCP, and particularly those who received platelet transfusions, experienced significantly greater clinical and economic burden compared to CLD patients without TCP. Safer and more cost-effective treatments to increase platelets are necessary.

Idioma originalEnglish (US)
Páginas (desde-hasta)378-385
Número de páginas8
PublicaciónJournal of Medical Economics
EstadoPublished - abr 2 2020

ASJC Scopus subject areas

  • Health Policy


Profundice en los temas de investigación de 'The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease'. En conjunto forman una huella única.

Citar esto